ST3
MCID: SPP010
MIFTS: 54

Suppressor of Tumorigenicity 3 (ST3)

Categories: Cancer diseases

Aliases & Classifications for Suppressor of Tumorigenicity 3

MalaCards integrated aliases for Suppressor of Tumorigenicity 3:

Name: Suppressor of Tumorigenicity 3 57 72
Cervical Carcinoma 57 13 55 17
Cervical Carcinoma, Tumor-Suppressor Gene Involved in; Ccts 57
Cervical Carcinoma, Tumor-Suppressor Gene Involved in 57
Tumor-Suppressor Gene, Hela Cell Type; Tshl 57
Tumor-Suppressor Gene, Hela Cell Type 57
Cervix Carcinoma 72
Tshl 57
Ccts 57
St3 57

Classifications:



External Ids:

OMIM 57 191181
UMLS 72 C0302592 C1860658

Summaries for Suppressor of Tumorigenicity 3

MalaCards based summary : Suppressor of Tumorigenicity 3, also known as cervical carcinoma, is related to cervix uteri carcinoma in situ and cervix carcinoma. An important gene associated with Suppressor of Tumorigenicity 3 is ST3 (Suppression Of Tumorigenicity 3), and among its related pathways/superpathways are GPCR Pathway and Cell Cycle, Mitotic. The drugs Topotecan and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

More information from OMIM: 191181

Related Diseases for Suppressor of Tumorigenicity 3

Diseases related to Suppressor of Tumorigenicity 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 485)
# Related Disease Score Top Affiliating Genes
1 cervix uteri carcinoma in situ 31.6 TP53 CDKN2A
2 cervix carcinoma 31.3 TP53 FHIT CDKN2A
3 cervical adenocarcinoma 31.0 TP53 CDKN2A CDKN1A
4 adenocarcinoma 31.0 TP53 RB1 MYC CDKN2A
5 keratinizing squamous cell carcinoma 30.6 TP53 CDKN2A
6 retinoblastoma 30.5 TP53 RB1 CDKN2A CDKN1A
7 anogenital venereal wart 30.3 UBE3A TP53 CDKN2A
8 anal squamous cell carcinoma 30.1 TP53 CDKN2A
9 ataxia-telangiectasia 30.1 TP53 PCNA CDKN1A
10 malignant mesenchymoma 29.9 TP53 FHIT CDKN1A
11 small cell cancer of the lung 29.9 TP53 RB1 MYC CDKN2A
12 skin melanoma 29.9 TP53 CDKN2A CDKN1A
13 lymphocytic leukemia 29.9 TP53 MYC BCL2
14 gallbladder cancer 29.8 TP53 FHIT CDKN2A
15 papilloma 29.7 UBE3A TP53 RB1 PCNA CDKN2A CDKN1A
16 oral cancer 29.6 TP53 PCNA CDKN2A
17 bladder cancer 29.5 TP53 RB1 MYC CDKN2A CDKN1A
18 glioblastoma multiforme 29.4 TP53 RB1 MYC CDKN2A CDKN1A
19 glioblastoma 29.4 TP53 RB1 MYC CDKN2A CDKN1A
20 soft tissue sarcoma 29.4 TP53 BCL2
21 cervix disease 29.0 UBE3A TP53 MYC FHIT CDKN2A
22 ovarian cancer 28.8 TP53 MYC CDKN1A BCL2 BAX
23 nasopharyngeal carcinoma 28.7 TP53 MYC CDKN2A CCNB1 BCL2
24 lung cancer susceptibility 3 28.7 TP53 FHIT CDKN2A CDKN1A CCNB1
25 squamous cell carcinoma, head and neck 28.6 TP53 RB1 MYC FHIT CDKN2A CDKN1A
26 endometrial cancer 28.5 TP53 RB1 MYC CDKN2A CDKN1A BCL2
27 cervical cancer 27.5 UBE3A TP53 RB1 MYC FHIT CDKN2A
28 hepatocellular carcinoma 27.3 TP53 RB1 MYC CDKN2A CDKN1A CCNB1
29 prostate cancer 27.1 TP53 RB1 MYC CDKN1A CCNB1 BCL2
30 esophageal cancer 27.0 TP53 RB1 MYC FHIT CDKN2A CDKN1A
31 breast cancer 26.4 TP53 RB1 PCNA MYC FHIT CDKN1A
32 colorectal cancer 26.3 TP53 MYC FHIT CDKN2A CDKN1A CCNB1
33 lung cancer 26.1 TP53 TAP1 RB1 PCNA MYC FHIT
34 cervical adenosquamous carcinoma 11.5
35 cataract 40 11.5
36 cataract, total congenital 11.2
37 high-grade neuroendocrine carcinoma of the cervix uteri 11.2
38 in situ carcinoma 10.8
39 cervical intraepithelial neoplasia 10.7
40 vulvar adenocarcinoma 10.7 TP53 RB1
41 squamous cell papilloma 10.6
42 bladder squamous cell carcinoma 10.6 TP53 CDKN2A
43 cervical squamous cell carcinoma 10.6
44 spitz nevus 10.5 TP53 CDKN2A
45 actinic cheilitis 10.5 TP53 CDKN1A
46 bladder carcinoma in situ 10.5 TP53 CDKN2A
47 gallbladder adenoma 10.5 RB1 CDKN2A
48 hepatic angiomyolipoma 10.5 RB1 MYC
49 scrotal carcinoma 10.5 TP53 CDKN2A
50 bladder transitional cell papilloma 10.5 TP53 CDKN1A

Graphical network of the top 20 diseases related to Suppressor of Tumorigenicity 3:



Diseases related to Suppressor of Tumorigenicity 3

Symptoms & Phenotypes for Suppressor of Tumorigenicity 3

Clinical features from OMIM:

191181

GenomeRNAi Phenotypes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 BAX BCL2 CDKN1A CDKN2A PCNA RB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 BAX BCL2 CDKN1A CDKN2A PCNA RB1
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 BAX BCL2 CCNB1 CDKN1A PCNA TP53

MGI Mouse Phenotypes related to Suppressor of Tumorigenicity 3:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.18 BAX BCL2 CDKN1A CDKN2A MYC PCNA
2 hematopoietic system MP:0005397 10.18 BAX BCL2 CDKN1A CDKN2A FHIT MYC
3 growth/size/body region MP:0005378 10.16 BAX BCL2 CDKN1A CDKN2A MYC PCNA
4 immune system MP:0005387 10.16 BAX BCL2 CDKN1A CDKN2A FHIT MYC
5 behavior/neurological MP:0005386 10.15 BAX BCL2 CDKN1A CDKN2A MYC RB1
6 mortality/aging MP:0010768 10.14 BAX BCL2 CDKN1A CDKN2A FHIT MYC
7 integument MP:0010771 10.09 BCL2 CDKN1A CDKN2A FHIT MYC RB1
8 digestive/alimentary MP:0005381 10.08 BCL2 CDKN1A CDKN2A FHIT MYC RB1
9 adipose tissue MP:0005375 10.03 BCL2 CDKN1A MYC PCNA RB1 TP53
10 hearing/vestibular/ear MP:0005377 9.97 BAX BCL2 CDKN1A MYC RB1 TP53
11 neoplasm MP:0002006 9.97 BAX BCL2 CDKN1A CDKN2A FHIT MYC
12 muscle MP:0005369 9.91 BAX BCL2 CDKN1A CDKN2A MYC RB1
13 nervous system MP:0003631 9.91 BAX BCL2 CDKN1A CDKN2A MYC RB1
14 no phenotypic analysis MP:0003012 9.7 CDKN1A CDKN2A MYC PCNA RB1 TP53
15 pigmentation MP:0001186 9.35 BCL2 CDKN2A MYC RB1 TP53
16 reproductive system MP:0005389 9.28 BAX BCL2 CDKN1A CDKN2A MYC PCNA

Drugs & Therapeutics for Suppressor of Tumorigenicity 3

Drugs for Suppressor of Tumorigenicity 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 234)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
2
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
5
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
6
leucovorin Approved Phase 3 58-05-9 143 6006
7
Gemcitabine Approved Phase 3 95058-81-4 60750
8
Nelfinavir Approved Phase 3 159989-64-7 64143
9
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
10
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
11
Bevacizumab Approved, Investigational Phase 3 216974-75-3
12
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
13
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
14
Ondansetron Approved Phase 3 99614-02-5 4595
15
acetic acid Approved Phase 3 64-19-7 176
16
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
17
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
18
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
19
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
20
Inulin Approved, Investigational, Nutraceutical Phase 3 9005-80-5 24763
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
23
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
25
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
26
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
27
Tirapazamine Investigational Phase 3 27314-97-2
28 Deoxyglucose Phase 3
29 topoisomerase I inhibitors Phase 3
30 Topoisomerase Inhibitors Phase 3
31 Antimetabolites Phase 3
32 Antimetabolites, Antineoplastic Phase 3
33 Antineoplastic Agents, Immunological Phase 3
34 Anti-Bacterial Agents Phase 2, Phase 3
35 Antibodies Phase 3
36 Immunoglobulins Phase 3
37 Anti-Inflammatory Agents Phase 3
38 glucocorticoids Phase 3
39 Peripheral Nervous System Agents Phase 3
40 Autonomic Agents Phase 3
41 Antibodies, Monoclonal Phase 3
42 Gastrointestinal Agents Phase 3
43 Immunoglobulin G Phase 3
44 Mitogens Phase 3
45 Endothelial Growth Factors Phase 3
46 Antiparasitic Agents Phase 2, Phase 3
47 Antiprotozoal Agents Phase 2, Phase 3
48 Antiemetics Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50 BB 1101 Phase 3

Interventional clinical trials:

(show top 50) (show all 191)
# Name Status NCT ID Phase Drugs
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
2 Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix Unknown status NCT01593306 Phase 3 Paclitaxel, Cisplatin;Cisplatin
3 Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
4 Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
5 Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma Unknown status NCT01000415 Phase 3
6 A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image Unknown status NCT00146458 Phase 3
7 A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy. Unknown status NCT01414517 Phase 3
8 Collaborative Corneal Transplantation Studies (CCTS) Completed NCT00000137 Phase 3
9 Phase III Study of S-1 + Cisplatin Compared With Single-agent Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix Completed NCT00770874 Phase 3 S-1 + Cisplatin (arm A);Cisplatin (arm B)
10 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
11 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
12 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
13 A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago Completed NCT01937650 Phase 2, Phase 3 Radiotherapy plus metronidazole
14 Preoperative Dexamethasone Reduces Postoperative Pain, Nausea and Vomiting Following Mastectomy for Breast Cancer. Completed NCT01116713 Phase 3 intravenous dexamethasone;Homologated placebo.
15 Phase III Clinical Trial: "Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma" Completed NCT02083211 Phase 3 mAb Nimotuzumab
16 Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer Recruiting NCT02595554 Phase 3 Paclitaxel;Cisplatin
17 An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma Recruiting NCT03257267 Phase 3 REGN2810;Investigator Choice (IC) Chemotherapy
18 A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix Recruiting NCT03556839 Phase 3 Atezolizumab;Bevacizumab;Cisplatin;Paclitaxel
19 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
20 A Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer(CSEM005) Recruiting NCT02629718 Phase 3 NACT (Paclitaxel + Cisplatin or carboplatin)
21 A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix. Recruiting NCT03256916 Phase 3 Nelfinavir;Cisplatin
22 The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Recruiting NCT03366493 Phase 3
23 Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer Recruiting NCT01561586 Phase 3 Weekly cisplatin with RT;Tri-weekly cisplatin with RT
24 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Recruiting NCT02669459 Phase 3 Imiquimod
25 Phase II/III Clinical Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma Active, not recruiting NCT01554397 Phase 2, Phase 3 Cisplatin
26 Multicenter Randomised Double-blind Study to Compare HR3 or Placebo in Combination With Cisplatin-navelbine for Patients With Cervical Carcinoma, Followed in Case of Progression by a Second Line. Active, not recruiting NCT03413579 Phase 3
27 Comparison of Different Adjuvant Treatments Following Radical Surgery in Early Stage Cervical Carcinoma Active, not recruiting NCT00806117 Phase 3
28 Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer. Active, not recruiting NCT01608451 Phase 3 Cholecalciferol;Inj. Progesterone
29 A Multicenter, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Carcinoma Not yet recruiting NCT03086681 Phase 3 Endostar;DDP
30 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
31 Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix. Unknown status NCT01973101 Phase 2 Cisplatin;Gemcitabine;cisplatin
32 An Exploratory Pharmacogenomic Study of Neoadjuvant Cetuximab Followed by Cisplatin, Radiotherapy, and Cetuximab in Women With Newly Diagnosed Locally Advanced or Metastatic Cervical Carcinoma Unknown status NCT00292955 Phase 2 Cetuximab
33 Vaccination of Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer With HLA-A1, -A2 and -B35 Restricted Survivin Peptides Unknown status NCT00108875 Phase 1, Phase 2
34 An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix Unknown status NCT02492503 Phase 1, Phase 2 Paclitaxel and carboplatin;Paclitaxel and carboplatin
35 Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma. Unknown status NCT00039884 Phase 2 NESP - Novel Erythropoiesis Stimulating Protein
36 A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Unknown status NCT01266460 Phase 2
37 Phase II Study Evaluating the Role of Tomotherapy- Based Intensity Modulated Radiotherapy and Brachytherapy in Postsurgery Recurrent Carcinoma Cervix Unknown status NCT01117402 Phase 2
38 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
39 HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Cervical Carcinoma: Clinical Trial Completed NCT02523365 Phase 1, Phase 2
40 A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00031993 Phase 2 erlotinib hydrochloride
41 A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix Completed NCT00190983 Phase 2 Pemetrexed
42 A Phase II Trial of Capecitabine and Docetaxel in the Treatment of Advanced and Recurrent Cervical Cancer Completed NCT00257348 Phase 2 Capecitabine;Docetaxel
43 Phase I/II Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma: Analysis of Prognostic Factors and Determinants of Response: A Pilot Study Completed NCT00184093 Phase 1, Phase 2 Gemcitabine
44 A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma Completed NCT00005999 Phase 2 arsenic trioxide
45 A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma Completed NCT00005070 Phase 2 irofulven
46 Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial) Completed NCT00931164 Phase 1, Phase 2 Sodium Oxybate
47 A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00041093 Phase 2 Docetaxel
48 Phase I/IIA, Open-Label, Safety, Tolerability, and Immunogenicity Study of INO-3112 Delivered by Electroporation (EP) in Women With Cervical Cancer After Chemoradiation for Newly Diagnosed Disease or Therapy for Recurrent and/or Persistent Disease Completed NCT02172911 Phase 1, Phase 2
49 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
50 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial of the Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix Completed NCT00285207 Phase 2 placebo;A007

Search NIH Clinical Center for Suppressor of Tumorigenicity 3

Genetic Tests for Suppressor of Tumorigenicity 3

Anatomical Context for Suppressor of Tumorigenicity 3

MalaCards organs/tissues related to Suppressor of Tumorigenicity 3:

41
Cervix, Lymph Node, Testes, Breast, Uterus, T Cells, Endothelial

Publications for Suppressor of Tumorigenicity 3

Articles related to Suppressor of Tumorigenicity 3:

(show top 50) (show all 10331)
# Title Authors PMID Year
1
Interstitial deletion of 11q13 sequences in HeLa cells. 38 8
10959095 2000
2
Deletion and translocation of chromosome 11q13 sequences in cervical carcinoma cell lines. 38 8
7887426 1995
3
Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. 38 8
8041728 1994
4
Loss of heterozygosity for alleles on chromosome II in cervical carcinoma. 38 8
1680288 1991
5
Genetic characteristics of the HeLa cell. 38 8
1246620 1976
6
Cell culture forensics. 8
11438719 2001
7
Short tandem repeat profiling provides an international reference standard for human cell lines. 8
11416159 2001
8
East Hela and West Hela, in memory of Stella Mamaeva, 1939-1995. 8
8964054 1996
9
Localization of HeLa cell tumor-suppressor gene to the long arm of chromosome II. 8
2577469 1989
10
Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids. 8
2877730 1986
11
Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. 8
2881780 1986
12
Suppression of tumorigenicity in somatic cell hybrids. III. Cosegregation of human chromosome 11 of a normal cell and suppression of tumorigenicity in intraspecies hybrids of normal diploid x malignant cells. 8
3956263 1986
13
Suppression of tumorigenicity. 8
7140370 1982
14
Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids. 8
7323948 1981
15
Cross-contamination of cells in culture. 8
6451928 1981
16
Suppression of tumorigenicity in somatic cell hybrids. I. Suppression and reexpression of tumorigenicity in diploid human X D98AH2 hybrids and independent segregation of tumorigenicity from other cell phenotypes. 8
6934067 1980
17
Characteristics of HeLa strains: permanent vs. variable features. 8
7002488 1980
18
Suppression of malignancy in human cells. 8
1264187 1976
19
HeLa cultures defined. 8
1246601 1976
20
Banded marker chromosomes as indicators of intraspecies cellular contamination. 8
4469665 1974
21
George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. 8
4942173 1971
22
Apparent Hela cell contamination of human heteroploid cell lines. 8
5641128 1968
23
MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. 9 38
20351093 2010
24
Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. 9 38
20067769 2010
25
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. 9 38
20429915 2010
26
Constitutive HIF-1 activity in malignant melanoma. 9 38
20185296 2010
27
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. 9 38
20395210 2010
28
HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. 9 38
20026098 2010
29
Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. 9 38
19953094 2010
30
Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. 9 38
19362787 2009
31
Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. 9 38
19935879 2009
32
HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. 9 38
19775342 2009
33
[Involvement of human papillomavirus in upper aero-digestive tracts cancers]. 9 38
19744917 2009
34
Identification of an active site of EMMPRIN for the augmentation of matrix metalloproteinase-1 and -3 expression in a co-culture of human uterine cervical carcinoma cells and fibroblasts. 9 38
19427027 2009
35
The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma. 9 38
19589137 2009
36
The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. 9 38
19563645 2009
37
Spatiotemporal activation of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and p53mt human cervical carcinoma cells. 9 38
19216720 2009
38
Antitumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA in malignant melanoma cells. 9 38
19441892 2009
39
Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. 9 38
19202550 2009
40
Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology. 9 38
19476635 2009
41
The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. 9 38
18716870 2009
42
[Inhibitive effect of E1A gene on the cell growth of human cervical carcinoma cell in vitro]. 9 38
19483289 2009
43
Differential tissue-specific protein markers of vaginal carcinoma. 9 38
19367286 2009
44
Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. 9 38
19327639 2009
45
Immunohistochemical studies of trophoblastic tumors. 9 38
19145204 2009
46
No association of TAP1 and TAP2 genes polymorphism with risk of cervical cancer in north Indian population. 9 38
19263211 2009
47
Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. 9 38
19251084 2009
48
Transition of cervical carcinoma in situ to invasive cancer: role of p16 INK4a expression in progression and in recurrence. 9 38
19100258 2009
49
Preliminary study of TIP47 as a possible new biomarker of cervical dysplasia and invasive carcinoma. 9 38
19331227 2009
50
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. 9 38
19148475 2009

Variations for Suppressor of Tumorigenicity 3

Expression for Suppressor of Tumorigenicity 3

Search GEO for disease gene expression data for Suppressor of Tumorigenicity 3.

Pathways for Suppressor of Tumorigenicity 3

Pathways related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 UBE3A TP53 RB1 MYC CDKN2A CDKN1A
2
Show member pathways
13.43 TP53 RB1 PCNA MYC CDKN2A CDKN1A
3
Show member pathways
13.04 UBE3A TP53 RB1 MYC CDKN1A BCL2
4
Show member pathways
13 TP53 PCNA CDKN2A CDKN1A CCNB1 BAX
5
Show member pathways
12.93 TP53 RB1 CDKN1A BCL2 BAX
6 12.91 TP53 RB1 MYC CDKN2A CDKN1A BCL2
7
Show member pathways
12.9 TP53 TAP1 RB1 PCNA MYC CDKN2A
8
Show member pathways
12.88 TP53 RB1 PCNA MYC CDKN2A CDKN1A
9
Show member pathways
12.86 TP53 MYC CDKN2A CDKN1A BCL2 BAX
10
Show member pathways
12.82 TP53 RB1 MYC CDKN2A CDKN1A BCL2
11
Show member pathways
12.76 TP53 RB1 FHIT CDKN2A CDKN1A BCL2
12
Show member pathways
12.7 TP53 RB1 PCNA MYC CDKN1A CCNB1
13
Show member pathways
12.65 TP53 RB1 BCL2 BAX
14
Show member pathways
12.63 TP53 MYC CDKN1A BCL2 BAX
15
Show member pathways
12.61 TP53 RB1 PCNA MYC CDKN2A CDKN1A
16 12.59 TP53 RB1 PCNA CDKN2A CDKN1A CCNB1
17 12.58 TP53 MYC CDKN2A CDKN1A BCL2
18
Show member pathways
12.46 TP53 PCNA MYC CDKN1A BAX
19
Show member pathways
12.42 TP53 CDKN1A BAX
20
Show member pathways
12.42 TP53 RB1 CDKN2A CDKN1A CCNB1
21 12.41 TP53 RB1 PCNA MYC CDKN2A CDKN1A
22 12.38 UBE3A TP53 RB1 CDKN2A CDKN1A BAX
23 12.36 TP53 RB1 PCNA MYC CDKN2A CDKN1A
24
Show member pathways
12.33 TP53 RB1 CDKN1A BCL2 BAX
25 12.29 TP53 MYC CDKN1A BAX
26
Show member pathways
12.29 TP53 RB1 MYC CDKN1A BCL2 BAX
27
Show member pathways
12.29 TP53 RB1 MYC CDKN2A CDKN1A CCNB1
28
Show member pathways
12.26 RB1 MYC CDKN2A CDKN1A
29 12.24 TP53 RB1 MYC BCL2 BAX
30 12.24 TP53 RB1 MYC CDKN2A CDKN1A CCNB1
31 12.23 TP53 MYC CDKN1A BAX
32 12.22 TP53 MYC CDKN1A BCL2 BAX
33 12.13 UBE3A TP53 RB1 CDKN2A CDKN1A BCL2
34
Show member pathways
12.11 TP53 MYC BAX
35 12.08 TP53 RB1 MYC CDKN2A CDKN1A
36 12.05 TP53 MYC CDKN1A
37
Show member pathways
12.05 MYC CDKN1A BCL2 BAX
38 12.05 TP53 MYC CDKN1A BCL2
39 12.05 TP53 MYC CDKN2A CDKN1A BCL2 BAX
40
Show member pathways
12.03 TP53 RB1 PCNA MYC CCNB1
41
Show member pathways
12.03 TP53 PCNA CDKN1A CCNB1 BAX
42
Show member pathways
12.02 TP53 BCL2 BAX
43 12 TP53 RB1 MYC
44 11.99 TP53 BCL2 BAX
45 11.98 TP53 RB1 PCNA CDKN2A CDKN1A BCL2
46
Show member pathways
11.97 TP53 BCL2 BAX
47 11.89 TP53 MYC CCNB1 BAX
48 11.87 UBE3A RB1 CDKN1A
49 11.86 MYC CDKN1A CCNB1 BCL2
50
Show member pathways
11.85 TP53 CDKN1A CCNB1

GO Terms for Suppressor of Tumorigenicity 3

Cellular components related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.9 UBE3A TP53 RB1 PCNA MYC FHIT
2 nucleoplasm GO:0005654 9.86 TP53 RB1 PCNA MYC CDKN2A CDKN1A
3 pore complex GO:0046930 8.96 BCL2 BAX
4 PCNA-p21 complex GO:0070557 8.62 PCNA CDKN1A

Biological processes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 MYC CDKN1A CCNB1 BCL2
2 cytokine-mediated signaling pathway GO:0019221 9.96 TP53 MYC CDKN1A BCL2
3 cellular response to DNA damage stimulus GO:0006974 9.95 TP53 PCNA MYC CDKN1A BCL2 BAX
4 viral process GO:0016032 9.93 UBE3A TP53 TAP1 RB1 PCNA BAX
5 cell proliferation GO:0008283 9.92 TP53 MYC BCL2 BAX
6 regulation of cell cycle GO:0051726 9.91 RB1 CCNB1 BCL2 BAX
7 negative regulation of cell proliferation GO:0008285 9.91 TP53 RB1 CDKN2A CDKN1A BCL2 BAX
8 cellular response to hypoxia GO:0071456 9.86 TP53 MYC CCNB1 BCL2
9 negative regulation of cell growth GO:0030308 9.85 TP53 CDKN2A CDKN1A BCL2
10 positive regulation of fibroblast proliferation GO:0048146 9.81 MYC CDKN1A CCNB1
11 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.81 RB1 CDKN1A BCL2
12 response to toxic substance GO:0009636 9.81 CDKN1A CCNB1 BCL2 BAX
13 regulation of mitotic cell cycle GO:0007346 9.8 RB1 MYC CDKN1A
14 G1/S transition of mitotic cell cycle GO:0000082 9.8 RB1 MYC CDKN2A CDKN1A
15 neuron apoptotic process GO:0051402 9.79 RB1 BCL2 BAX
16 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.78 TP53 BCL2 BAX
17 negative regulation of fibroblast proliferation GO:0048147 9.77 TP53 MYC BAX
18 intrinsic apoptotic signaling pathway GO:0097193 9.76 TP53 CDKN1A BAX
19 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.71 TP53 FHIT BAX
20 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.7 CDKN2A CDKN1A
21 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.7 TP53 BCL2
22 negative regulation of apoptotic signaling pathway GO:2001234 9.7 BCL2 BAX
23 apoptotic mitochondrial changes GO:0008637 9.7 CDKN2A BCL2 BAX
24 cellular senescence GO:0090398 9.69 CDKN2A CDKN1A
25 B cell homeostasis GO:0001782 9.69 BCL2 BAX
26 release of cytochrome c from mitochondria GO:0001836 9.69 BCL2 BAX
27 positive regulation of smooth muscle cell migration GO:0014911 9.68 MYC BCL2
28 negative regulation of phosphorylation GO:0042326 9.68 CDKN2A CDKN1A
29 positive regulation of protein oligomerization GO:0032461 9.68 TP53 BAX
30 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.68 BCL2 BAX
31 hypothalamus development GO:0021854 9.67 MYC BAX
32 regulation of mitochondrial membrane permeability GO:0046902 9.67 TP53 BCL2
33 Ras protein signal transduction GO:0007265 9.67 TP53 RB1 CDKN2A CDKN1A
34 regulation of protein heterodimerization activity GO:0043497 9.66 BCL2 BAX
35 regulation of protein homodimerization activity GO:0043496 9.65 BCL2 BAX
36 leukocyte homeostasis GO:0001776 9.65 BCL2 BAX
37 cell cycle arrest GO:0007050 9.65 TP53 RB1 MYC CDKN2A CDKN1A
38 signal transduction by p53 class mediator GO:0072331 9.64 TP53 CDKN1A
39 cellular response to UV GO:0034644 9.62 TP53 PCNA MYC BAX
40 regulation of nitrogen utilization GO:0006808 9.58 BCL2 BAX
41 replicative senescence GO:0090399 9.58 TP53 CDKN2A CDKN1A
42 positive regulation of developmental pigmentation GO:0048087 9.57 BCL2 BAX
43 ovarian follicle development GO:0001541 9.46 UBE3A MYC BCL2 BAX
44 response to gamma radiation GO:0010332 9.26 TP53 MYC BCL2 BAX
45 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.02 TP53 PCNA CDKN1A CCNB1 BAX
46 apoptotic process GO:0006915 10.08 TP53 RB1 FHIT CDKN2A BCL2 BAX
47 cell cycle GO:0007049 10.05 TP53 RB1 CDKN2A CDKN1A CCNB1

Molecular functions related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 TP53 RB1 PCNA FHIT BCL2 BAX
2 protein kinase binding GO:0019901 9.73 TP53 CDKN2A CDKN1A CCNB1
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.37 CDKN2A CDKN1A
4 transcription factor binding GO:0008134 9.35 TP53 RB1 MYC CDKN2A BCL2
5 disordered domain specific binding GO:0097718 9.33 TP53 RB1 CDKN2A
6 BH3 domain binding GO:0051434 9.26 BCL2 BAX
7 ubiquitin protein ligase binding GO:0031625 9.02 TP53 RB1 FHIT CDKN1A BCL2
8 protein binding GO:0005515 10.18 UBE3A TP53 TAP1 RB1 PCNA MYC

Sources for Suppressor of Tumorigenicity 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....